Microbiological analysis of chronic dacryocystitis.
OBJECTIVE
To investigate the microbiology of specimens from patients with chronic dacryocystitis.


METHODS
A total of 100 samples were obtained from the contents of the lacrimal duct in 91 consecutive patients with chronic dacryocystitis, including nine bilateral cases. These samples were cultured for aerobic and anaerobic bacteria and fungi with a routine microbiological technique. Positive cultured isolates were identified.


RESULTS
A total of 180 strains were isolated from the 85 bacterial samples, including 150 strains of aerobic bacteria and 30 strains of anaerobic bacteria. Fungi were found in eight samples and actinomyces in three samples. The bacterial species that were most frequently found were Staphylococcus species, representing 34.5% of all strains, followed by Corynebacterium diphtheroides (15.5%). The sensitivity tests revealed that levo-ofloxacin and amikacin were the most effective antibiotics.


CONCLUSIONS
Gram positive cocci was the predominant pathogen of chronic dacryocystitis. Levo-ofloxacin and amikacin had the best effect in vitro.
Sun
Xuguang
X
Department of Eye Microbiology, Beijing Institute of Ophthalmology, China. sunxuguang@yahoo.com
Liang
Qingfeng
Q
Luo
Shiyun
S
Wang
Zhiqun
Z
Li
Ran
R
Jin
Xiuying
X
D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001420:Bacteria, Aerobic / Q000302:isolation & purification; D001421:Bacteria, Anaerobic / Q000302:isolation & purification; D002908:Chronic Disease; D003353:Corynebacterium diphtheriae / Q000302:isolation & purification; D003607:Dacryocystitis / Q000188:drug therapy / Q000382:microbiology*; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007765:Lacrimal Apparatus / Q000382:microbiology*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use; D013210:Staphylococcus / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D000583:Amikacin; D015242:Ofloxacin